CA3181776A1 - Anti-pd-1 antibodies - Google Patents

Anti-pd-1 antibodies

Info

Publication number
CA3181776A1
CA3181776A1 CA3181776A CA3181776A CA3181776A1 CA 3181776 A1 CA3181776 A1 CA 3181776A1 CA 3181776 A CA3181776 A CA 3181776A CA 3181776 A CA3181776 A CA 3181776A CA 3181776 A1 CA3181776 A1 CA 3181776A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
antibody
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3181776A
Other languages
English (en)
French (fr)
Inventor
David A. Blair
Nicole K. GARAFFA
Pankaj Gupta
Priyanka Gupta
Fei Han
Aaron Timothy KARLAK
Dongmei Liu
Ivo Lorenz
Mouhamadou Lamine MBOW
Miguel E. MORENO-GARCIA
Joseph A. MOZDZIERZ
Kerry L. M. Ralph
Abdulsalam SHAABAN
Della M. WHITE
Helen Haixia Wu
Guangwei Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CA3181776A1 publication Critical patent/CA3181776A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3181776A 2020-05-26 2021-05-24 Anti-pd-1 antibodies Pending CA3181776A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063029962P 2020-05-26 2020-05-26
US63/029,962 2020-05-26
US202063039686P 2020-06-16 2020-06-16
US63/039,686 2020-06-16
PCT/US2021/033823 WO2021242663A1 (en) 2020-05-26 2021-05-24 Anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
CA3181776A1 true CA3181776A1 (en) 2021-12-02

Family

ID=76808128

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3181776A Pending CA3181776A1 (en) 2020-05-26 2021-05-24 Anti-pd-1 antibodies

Country Status (31)

Country Link
US (2) US12312405B2 (https=)
EP (2) EP4157876B1 (https=)
JP (2) JP7512433B2 (https=)
KR (1) KR102871588B1 (https=)
CN (3) CN115956087B (https=)
AU (1) AU2021280232B2 (https=)
BR (1) BR112022023989A2 (https=)
CA (1) CA3181776A1 (https=)
CL (1) CL2022003304A1 (https=)
CO (1) CO2022018416A2 (https=)
CR (1) CR20220596A (https=)
DK (1) DK4157876T3 (https=)
DO (1) DOP2022000264A (https=)
EC (1) ECSP22092185A (https=)
ES (1) ES2994127T3 (https=)
FI (1) FI4157876T3 (https=)
HR (1) HRP20241488T1 (https=)
HU (1) HUE069403T2 (https=)
IL (1) IL298431A (https=)
JO (1) JOP20220320B1 (https=)
LT (1) LT4157876T (https=)
MA (1) MA59827B1 (https=)
MX (1) MX2022014974A (https=)
PE (1) PE20231076A1 (https=)
PH (1) PH12022553181A1 (https=)
PL (1) PL4157876T3 (https=)
PT (1) PT4157876T (https=)
RS (1) RS66193B1 (https=)
SI (1) SI4157876T1 (https=)
TW (1) TWI859446B (https=)
WO (1) WO2021242663A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220596A (es) 2020-05-26 2023-01-23 Boehringer Ingelheim Int Anticuerpos anti-pd-1
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
KR20240137086A (ko) * 2022-01-28 2024-09-19 조지아뮨 인코포레이티드 Pd-1 작용제인 세포예정사 단백질 1에 대한 항체
WO2026008665A1 (en) * 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US266710A (en) 1882-10-31 Fastening for pocket-books
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
US20040241745A1 (en) 2001-07-31 2004-12-02 Tasuku Honjo Substance specific to pd-1
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
WO2009026472A1 (en) 2007-08-21 2009-02-26 The General Hospital Corporation Methods for inducing tolerance
WO2009067812A1 (en) 2007-11-28 2009-06-04 Universite De Montreal Pd-1 modulation and uses thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
US9181342B2 (en) * 2008-09-12 2015-11-10 Isis Innovation Limited PD-1 specific antibodies and uses thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
CN103620032B (zh) 2010-12-31 2016-02-24 生物蛋白有限公司 抗体的快速人源化
ES2893855T3 (es) 2011-08-11 2022-02-10 Ono Pharmaceutical Co Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
KR102357893B1 (ko) 2014-08-05 2022-02-04 맵퀘스트 에스아 Pd-1 에 결합하는 면역학적 시약
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
KR20180019725A (ko) 2015-06-23 2018-02-26 메모리얼 슬로안-케터링 캔서 센터 신규의 피디 1 면역 조절제
CN106699888B (zh) 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
ES2924402T3 (es) 2015-10-02 2022-10-06 Symphogen As Anticuerpos anti-PD-1 y composiciones
ES2895034T3 (es) 2015-10-02 2022-02-17 Hoffmann La Roche Anticuerpos anti-PD1 y procedimientos de uso
WO2017079080A1 (en) 2015-11-02 2017-05-11 The Johns Hopkins University Method of preventing organ transplant rejections using agonists to the pd-1 checkpoint pathway
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
US10759859B2 (en) 2016-01-14 2020-09-01 Bps Bioscience, Inc. Anti-PD-1 antibodies and uses thereof
US11299751B2 (en) * 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3470424B1 (en) 2016-06-08 2025-04-23 Shanghai Jiao Tong University School of Medicine Sequence of antibody heavy chain constant region for enhancing agonist antibody activity
RU2656181C1 (ru) 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
MY192158A (en) * 2016-09-14 2022-08-03 Abbvie Biotherapeutics Inc Anti-pd-1 antibodies and their uses
PE20191076A1 (es) 2016-09-14 2019-08-20 Beijing hanmi pharm co ltd Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
MX2019002867A (es) 2016-09-19 2019-11-12 Celgene Corp Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
PT3515938T (pt) 2016-09-21 2025-04-10 Cstone Pharmaceuticals Shanghai Co Ltd Anticorpos monoclonais contra morte programada 1 (pd-1)
CN114456269A (zh) 2016-09-21 2022-05-10 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
JP2019533458A (ja) 2016-11-01 2019-11-21 アナプティスバイオ インコーポレイティッド プログラム死１（ｐｄ−１）に対する抗体
HRP20211703T1 (hr) 2016-11-02 2022-02-04 Jounce Therapeutics, Inc. Protutijela protiv pd-1 i njihova upotreba
DK3541841T3 (da) 2016-11-18 2024-10-21 Servier Lab Anti-PD-1-antistoffer og sammensætninger
CN106519034B (zh) 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
EP3565841A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
AU2018206481B2 (en) 2017-01-09 2025-02-27 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
MX2019008348A (es) * 2017-01-18 2019-10-21 Genentech Inc Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas.
JP7275030B2 (ja) * 2017-01-20 2023-05-17 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 抗ｐｄ－１抗体およびその使用
CN108341871A (zh) 2017-01-24 2018-07-31 三生国健药业（上海）股份有限公司 抗pd-1单克隆抗体及其制备方法和应用
WO2018183459A1 (en) 2017-03-29 2018-10-04 Celgene Corporation Formulations comprising pd-1 binding proteins and methods of making thereof
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
TW201902514A (zh) 2017-06-05 2019-01-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso
EP4029877B1 (en) 2017-08-03 2024-01-17 Amgen Inc. Interleukin-21 muteins and methods of treatment
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
AR114127A1 (es) 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
IL277095B2 (en) 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
WO2019179421A1 (en) 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules
WO2019179390A1 (en) 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/egfr antibody molecules
WO2019179391A1 (en) 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules
WO2019179434A1 (en) 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/cd47 antibody molecules
EP3768724A4 (en) 2018-03-20 2022-04-13 Wuxi Biologics Ireland Limited. NEW ANTI-PD-1 ANTIBODIES
CN112236455B (zh) 2018-05-17 2023-05-16 南京维立志博生物科技有限公司 结合pd-1的抗体及其用途
US12258407B2 (en) 2018-07-19 2025-03-25 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-PD-1 antibodies, dosages and uses thereof
CN113861295B (zh) * 2018-07-20 2024-05-24 厦门大学 抗pd-1抗体及其用途
EP3876978A4 (en) 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
US12234289B2 (en) 2018-12-07 2025-02-25 Ono Pharmaceutical Co., Ltd. Immunosuppresive agent
TWI862565B (zh) 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
CN110577599A (zh) 2019-05-13 2019-12-17 深圳市润科生物科技有限公司 人源抗程序性死亡-1(pd-1)抗体及其应用
KR20250126805A (ko) 2019-06-05 2025-08-25 아납티스바이오, 아이엔씨. Pd-1 작용제 및 이의 사용 방법
CA3143636A1 (en) 2019-07-12 2021-01-21 Michael Lim Compositions and methods for treating cerebral vasospasm
US20220332825A1 (en) 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein
BR112022003163A2 (pt) 2019-08-19 2022-05-17 Pandion Operations Inc Imunotolerância alvejada com um agonista de pd-1
EP4079763A4 (en) 2019-12-20 2023-10-11 Guangdong Feipeng Pharmaceutical Co., Ltd MONOCLONAL ANTIBODY AGAINST HUMAN PROGRAMMED DEATH-1 (PD-1)
SI4076385T1 (sl) 2019-12-20 2026-04-30 Formycon Ag Formulacije protiteles anti-pd1
CN110787292B (zh) 2020-01-06 2020-04-24 上海复宏汉霖生物技术股份有限公司 一种细胞程序性死亡受体1抗体制剂及其用途
KR20210097882A (ko) 2020-01-30 2021-08-10 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
CN113456582B (zh) 2020-03-30 2024-06-14 鲁南制药集团股份有限公司 重组人源化抗pd-1单克隆抗体的液体制剂
US20230183347A1 (en) 2020-05-25 2023-06-15 Foundation For Biomedical Research And Innovation At Kobe PD-1 Agonist-Containing Pharmaceutical Composition for Treating or PReventing TH2-Mediated Disease
CR20220596A (es) 2020-05-26 2023-01-23 Boehringer Ingelheim Int Anticuerpos anti-pd-1
CN113797330A (zh) 2020-06-11 2021-12-17 三生国健药业（上海）股份有限公司 一种抗pd-1单克隆抗体液体制剂
PH12022552898A1 (en) 2020-06-19 2023-12-04 Sinocelltech Ltd Stable formulation for recombinant anti-pd-1 monoclonal antibody
CN111956799A (zh) 2020-09-18 2020-11-20 生物抗素公司 抗pd-1抗体和/或pd-l1抗体在制备治疗帕金森病药物中的应用

Also Published As

Publication number Publication date
MA59827B1 (fr) 2024-10-31
US12312405B2 (en) 2025-05-27
DK4157876T3 (da) 2024-10-28
ECSP22092185A (es) 2023-01-31
TW202216765A (zh) 2022-05-01
LT4157876T (lt) 2024-10-25
MX2022014974A (es) 2023-01-11
EP4464383A3 (en) 2025-02-26
TWI859446B (zh) 2024-10-21
CN121717905A (zh) 2026-03-24
IL298431A (en) 2023-01-01
SI4157876T1 (sl) 2025-01-31
CR20220596A (es) 2023-01-23
CN121930345A (zh) 2026-04-28
EP4464383A2 (en) 2024-11-20
US20260070984A1 (en) 2026-03-12
JP7777632B2 (ja) 2025-11-28
HRP20241488T1 (hr) 2025-02-14
RS66193B1 (sr) 2024-12-31
CN115956087A (zh) 2023-04-11
PE20231076A1 (es) 2023-07-17
KR102871588B1 (ko) 2025-10-17
BR112022023989A2 (pt) 2023-02-07
HUE069403T2 (hu) 2025-03-28
ES2994127T3 (en) 2025-01-17
CL2022003304A1 (es) 2023-04-14
JP2024125366A (ja) 2024-09-18
CO2022018416A2 (es) 2022-12-30
DOP2022000264A (es) 2023-01-31
KR20230015997A (ko) 2023-01-31
JP7512433B2 (ja) 2024-07-08
FI4157876T3 (fi) 2024-10-25
JOP20220320B1 (ar) 2025-10-01
PT4157876T (pt) 2024-10-21
EP4157876A1 (en) 2023-04-05
PH12022553181A1 (en) 2024-03-04
EP4157876B1 (en) 2024-09-04
AU2021280232A1 (en) 2022-12-15
JP2023528778A (ja) 2023-07-06
PL4157876T3 (pl) 2025-02-03
AU2021280232B2 (en) 2026-02-05
CN115956087B (zh) 2025-11-07
US20210380696A1 (en) 2021-12-09
WO2021242663A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
AU2021280232B2 (en) Anti-PD-1 antibodies
US20210284739A1 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
US12103967B2 (en) Bispecific anti-CCL2 antibodies
US20150355199A1 (en) Agents, kits and methods for complement factor h-related protein 1 detection
HK40112204A (en) Anti-pd-1 antibodies
HK40082160B (en) Anti-pd-1 antibodies
HK40082160A (en) Anti-pd-1 antibodies
EA052706B1 (ru) Антитела к pd-1
US20240425575A1 (en) Anti-ang2 antibody, preparation method therefor, and application thereof
KR20240021859A (ko) 이중특이적 항-ccl2 항체
HK40112237A (zh) 双特异性抗ccl2抗体
HK40077249A (en) Bispecific anti-ccl2 antibodies

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250502

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250502

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250505

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250505

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250522

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250522

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250522

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250523